Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Search
Our Mission
Our Story
Therapeutics
Therapeutics
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD
Celebrating Innovation | Partnering
BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.
Veterinary Public Health
Veterinary Public Health
Sarcoma: An expert’s perspective
Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, shares his expert perspectives on sarcoma, the importance of early detection, and his hopes for the sarcoma treatment landscape.
Life forward - Boehringer Ingelheim unveils its evolved company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Taking patient centricity to new heights
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
Our Businesses
Our Businesses
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
PAP Resources
PAP Resources
Our Culture of Caring: Volunteering
At BI we are committed to improving the health and well-being of people & animals. We encourage & support employee volunteer activities.
Clinical trials deliver medical breakthroughs – but how do they happen?
Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.
Giving Back to Those Who Serve Our Country
Giving Back to Those Who Serve Our Country
Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned
Boehringer Ingelheim grows faster than the pharmaceutical market for the tenth time in succession / continued high level of investment in research and development / market launch of five innovative medicines planned
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US
BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US
Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care